Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2016-11-10 Investor Presentation
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Investor Presentation 2016
Investor Presentation Classification · 98% confidence The document is titled "Biotest AG. Analyst Conference Q1-Q3 2016 Frankfurt November 10" and contains detailed financial highlights (Sales, EBIT, EBITDA, Cash Flow) for the first nine months of 2016, along with slides on R&D projects and product pipelines. This structure—a presentation summarizing period performance with key figures and strategic updates—is characteristic of an Investor Presentation (IP). It is not a full regulatory report (like 10-K or IR) nor a brief announcement of a report (RPA/RNS). The content is clearly designed for investors.
2016-11-10 German
Investor Presentation 2016
Investor Presentation Classification · 98% confidence The document is titled "Biotest AG. Analyst Conference Q1-Q3 2016 Frankfurt November 10" and contains detailed financial highlights (Sales, EBIT, EBITDA, Cash Flow) for the first nine months of 2016, along with slides on R&D projects and product pipelines. This structure—a presentation summarizing period performance with key figures and strategic updates—is characteristic of an Investor Presentation (IP). It is not a full regulatory report (like 10-K or IR) nor a brief announcement of a report (RPA/RNS). The content is clearly designed for investors.
2016-11-10 English
Q3 statement / Q3 financial report 2016
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' for the 9-month period ending 30 September 2016. It contains detailed financial tables (Revenue, EBIT, Cash Flow, Statement of Financial Position), management commentary on business performance, and research and development updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2016
2016-11-10 German
Biotest AG: First patient treated in global clinical phase III study of IgG Next Generation in the indication Primary Immunodeficiency Disease (PID)
Legal Proceedings Report Classification · 99% confidence The document is a press release dated November 8, 2016, announcing that the first patient has been treated in a global clinical phase III study for a new immunoglobulin product (IgG Next Generation) for Primary Immunodeficiency Disease (PID). It details the study design, regulatory discussions (FDA, PEI), and provides background on the disease and the company's product pipeline. This content is a specific update on research and development progress, which is typically disseminated via a general news release or regulatory filing. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific investor presentation (IP), the most appropriate classification is a general Regulatory Filing (RNS) as it is a formal corporate news announcement disseminated via DGAP, or potentially a Research Update if that were an option. Given the provided list, RNS serves as the best fit for a significant, non-financial, regulatory-adjacent corporate announcement.
2016-11-08 English
Biotest AG: Altered tax assessments for 2005-2008 lead to a decrease of claims against Biotest AG - proceedings against Biotest AG are close to be completed
Legal Proceedings Report Classification · 99% confidence The document is an 'Ad-hoc RELEASE' announcing an update regarding altered tax assessments and the near completion of legal proceedings related to Russian business activities. It explicitly mentions disclosure under Article 17 of the European Market Abuse Regulation (MAR). This type of material, which provides timely, material information outside of scheduled financial reports (like 10-K or IR), typically falls under general regulatory announcements or specific legal/material event disclosures. Since the core content is a significant legal/regulatory development (tax assessment changes and ongoing investigations/fines), it aligns best with the 'Legal Proceedings Report' (LTR) category, as it details the status and financial impact of legal/regulatory matters. It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Given the focus on legal proceedings and regulatory interaction, LTR is the most precise fit among the specific options.
2016-11-04 English
Biotest AG: Biotest AG will offer recombinant factor VIII from 2017
Regulatory Filings Classification · 100% confidence The document is a press release dated November 3, 2016, announcing a business development: Biotest AG will offer recombinant factor VIII starting in 2017 through a cooperation with Octapharma. It details the product, its indication, and the strategic rationale. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a general corporate announcement regarding a product/alliance strategy. Since it is a specific corporate news item that doesn't fit the definitions for ER, IR, CAP, MANG, or DIV, it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous corporate news disseminated via services like DGAP, especially when the content is primarily operational/strategic news rather than a formal financial report or mandatory disclosure.
2016-11-03 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.